NCT07702890: A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

Sponsor: Gubra A/S. Phase: PHASE1. Conditions: Obesity, Type 2 Diabetes